Fortress Biotech, Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Fortress Biotech, Inc. (FBIO) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$18.78 million for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-09.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-11-09
- Fortress Biotech, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was -$3.25M.
- Fortress Biotech, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-06-30 was -$25.63M, a 348.44% decline year-over-year.
- Fortress Biotech, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-03-31 was $10.11M, a 77.91% decline year-over-year.
- Fortress Biotech, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was -$32.78M, a 392.67% decline year-over-year.
- Fortress Biotech, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$9.89M, a 120.42% decline from fiscal 2015.
- Fortress Biotech, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $48.42M.
- Fortress Biotech, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2014 was -$49.76M, a 183.88% decline from fiscal 2013.
- Fortress Biotech, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2013 was $59.32M, a 248.15% increase from fiscal 2012.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 12 month | Cash and Cash Equivalents, Period Increase (Decrease) 63 month | Cash and Cash Equivalents, Period Increase (Decrease) 66 month | Cash and Cash Equivalents, Period Increase (Decrease) 69 month | Cash and Cash Equivalents, Period Increase (Decrease) 72 month | Cash and Cash Equivalents, Period Increase (Decrease) 75 month | Cash and Cash Equivalents, Period Increase (Decrease) 78 month | Cash and Cash Equivalents, Period Increase (Decrease) 81 month | Cash and Cash Equivalents, Period Increase (Decrease) 84 month | Cash and Cash Equivalents, Period Increase (Decrease) 87 month | Cash and Cash Equivalents, Period Increase (Decrease) 90 month | Cash and Cash Equivalents, Period Increase (Decrease) 93 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2018-09-30 | -$3.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | -$28.89M derived: sum of 2 quarters · filed 2018-11-09 | -$18.78M 10-Q · filed 2018-11-09 | ||||||||||||||
| 2018-06-30 | -$25.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | -$15.53M 10-Q · filed 2018-08-09 | |||||||||||||||
| 2018-03-31 | $10.11M 10-Q · filed 2018-05-10 | ||||||||||||||||
| 2017-09-30 | -$32.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | -$22.46M derived: sum of 2 quarters · filed 2018-11-09 | $23.28M 10-Q · filed 2018-11-09 | $22.24M 10-Q · filed 2017-11-09 | $29.04M derived: sum of 4 quarters · filed 2018-11-09 | ||||||||||||
| 2017-06-30 | $10.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $56.06M 10-Q · filed 2018-08-09 | $56.05M 10-Q · filed 2017-08-09 | $61.82M derived: sum of 3 quarters · filed 2018-08-09 | $73.02M derived: sum of 4 quarters · filed 2018-08-09 | ||||||||||||
| 2017-03-31 | $45.74M 10-Q · filed 2018-05-10 | $51.50M derived: sum of 2 quarters · filed 2018-05-10 | $62.70M derived: sum of 3 quarters · filed 2018-05-10 | $52.62M derived: sum of 4 quarters · filed 2018-05-10 | |||||||||||||
| 2016-12-31 | $5.76M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $16.96M derived: sum of 2 quarters · filed 2017-11-09 | $6.88M derived: sum of 3 quarters · filed 2017-11-09 | -$9.89M 10-K · filed 2017-03-16 | |||||||||||||
| 2016-09-30 | $11.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $1.12M derived: sum of 2 quarters · filed 2017-11-09 | -$15.64M 10-Q · filed 2017-11-09 | $56.97M derived: sum of 4 quarters · filed 2017-11-09 | |||||||||||||
| 2016-06-30 | -$10.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | -$26.85M 10-Q · filed 2017-08-09 | $45.77M derived: sum of 3 quarters · filed 2017-08-09 | $30.30M derived: sum of 4 quarters · filed 2017-08-09 | |||||||||||||
| 2016-03-31 | -$16.77M 10-Q · filed 2017-05-10 | $55.85M derived: sum of 2 quarters · filed 2017-05-10 | $40.38M derived: sum of 3 quarters · filed 2017-05-10 | $32.49M derived: sum of 4 quarters · filed 2017-05-10 | |||||||||||||
| 2015-12-31 | $72.62M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $57.15M derived: sum of 2 quarters · filed 2017-03-16 | $49.25M derived: sum of 3 quarters · filed 2017-03-16 | $48.42M 10-K · filed 2017-03-16 | |||||||||||||
| 2015-09-30 | -$15.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$23.36M derived: sum of 2 quarters · filed 2016-11-09 | -$24.20M 10-Q · filed 2016-11-09 | -$46.03M derived: sum of 4 quarters · filed 2017-03-16 | |||||||||||||
| 2015-06-30 | -$7.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | -$8.72M 10-Q · filed 2016-08-09 | -$30.55M derived: sum of 3 quarters · filed 2017-03-16 | -$34.76M derived: sum of 4 quarters · filed 2017-03-16 | |||||||||||||
| 2015-03-31 | -$831.00K 10-Q · filed 2016-05-10 | -$22.66M derived: sum of 2 quarters · filed 2017-03-16 | -$26.87M derived: sum of 3 quarters · filed 2017-03-16 | -$31.05M derived: sum of 4 quarters · filed 2017-03-16 | |||||||||||||
| 2014-12-31 | -$21.83M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$26.04M derived: sum of 2 quarters · filed 2017-03-16 | -$30.22M derived: sum of 3 quarters · filed 2017-03-16 | -$49.76M 10-K · filed 2017-03-16 | |||||||||||||
| 2014-09-30 | -$4.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | -$8.39M derived: sum of 2 quarters · filed 2015-11-09 | -$27.93M 10-Q · filed 2015-11-09 | -$34.67M derived: sum of 4 quarters · filed 2016-03-15 | |||||||||||||
| 2014-06-30 | -$4.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | -$23.72M 10-Q · filed 2015-08-10 | -$30.47M derived: sum of 3 quarters · filed 2016-03-15 | $7.91M derived: sum of 4 quarters · filed 2016-03-15 | |||||||||||||
| 2014-03-31 | -$19.54M 10-Q · filed 2015-05-11 | -$26.29M derived: sum of 2 quarters · filed 2016-03-15 | $12.10M derived: sum of 3 quarters · filed 2016-03-15 | $35.93M derived: sum of 4 quarters · filed 2016-03-15 | $79.98M 10-Q · filed 2014-05-12 | ||||||||||||
| 2013-12-31 | -$6.75M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $31.64M derived: sum of 2 quarters · filed 2016-03-15 | $55.47M derived: sum of 3 quarters · filed 2016-03-15 | $59.32M 10-K · filed 2016-03-15 | $99.52M 10-K · filed 2014-03-14 | ||||||||||||
| 2013-09-30 | $38.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $62.22M derived: sum of 2 quarters · filed 2014-11-06 | $66.07M 10-Q · filed 2014-11-06 | $58.79M derived: sum of 4 quarters · filed 2015-03-16 | $106.27M 10-Q · filed 2013-11-01 | ||||||||||||
| 2013-06-30 | $23.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $27.69M 10-Q · filed 2014-08-11 | $20.41M derived: sum of 3 quarters · filed 2015-03-16 | $29.68M derived: sum of 4 quarters · filed 2015-03-16 | $67.89M 10-Q · filed 2013-08-05 | ||||||||||||
| 2013-03-31 | $3.85M 10-Q · filed 2014-05-12 | -$3.43M derived: sum of 2 quarters · filed 2015-03-16 | $5.84M derived: sum of 3 quarters · filed 2015-03-16 | $26.32M derived: sum of 4 quarters · filed 2015-03-16 | $44.05M 10-Q · filed 2013-05-09 | ||||||||||||
| 2012-12-31 | -$7.28M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | $1.99M derived: sum of 2 quarters · filed 2015-03-16 | $22.46M derived: sum of 3 quarters · filed 2015-03-16 | $17.04M 10-K · filed 2015-03-16 | $40.20M 10-K · filed 2013-03-18 | ||||||||||||
| 2012-09-30 | $9.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-01 | $29.74M derived: sum of 2 quarters · filed 2013-11-01 | $24.32M 10-Q · filed 2013-11-01 | $20.77M derived: sum of 4 quarters · filed 2014-03-14 | $47.48M 10-Q · filed 2012-11-14 | ||||||||||||
| 2012-06-30 | $20.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-05 | $15.05M 10-Q · filed 2013-08-05 | $11.50M derived: sum of 3 quarters · filed 2014-03-14 | $8.56M derived: sum of 4 quarters · filed 2014-03-14 | $38.21M 10-Q · filed 2012-08-08 | ||||||||||||
| 2012-03-31 | -$5.42M 10-Q · filed 2013-05-09 | -$8.97M derived: sum of 2 quarters · filed 2014-03-14 | -$11.91M derived: sum of 3 quarters · filed 2014-03-14 | $8.47M derived: sum of 4 quarters · filed 2014-03-14 | $17.73M 10-Q · filed 2012-05-15 | ||||||||||||
| 2011-12-31 | -$3.55M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-14 | -$6.49M derived: sum of 2 quarters · filed 2014-03-14 | $13.89M derived: sum of 3 quarters · filed 2014-03-14 | $8.30M 10-K · filed 2014-03-14 | $23.16M 10-K · filed 2012-03-29 | ||||||||||||
| 2011-09-30 | -$2.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-14 | $17.44M derived: sum of 2 quarters · filed 2012-11-14 | $11.85M 10-Q · filed 2012-11-14 | $10.92M derived: sum of 4 quarters · filed 2013-03-18 | $26.71M 10-Q · filed 2011-11-14 | ||||||||||||
| 2011-06-30 | $20.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-08 | $14.79M 10-Q · filed 2012-08-08 | $13.86M derived: sum of 3 quarters · filed 2013-03-18 | ||||||||||||||
| 2011-03-31 | -$5.59M 10-Q · filed 2012-05-15 | -$6.51M derived: sum of 2 quarters · filed 2013-03-18 | |||||||||||||||
| 2010-12-31 | -$922.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $13.35M 10-K · filed 2013-03-18 | |||||||||||||||
| 2010-09-30 | $14.27M 10-Q · filed 2011-11-14 | ||||||||||||||||
| 2009-12-31 | $1.50M 10-K · filed 2012-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |